1. Introduction
A well-functioning vascular access (VA) is a certain requirement for providing life-sustaining hemodialysis treatment in end-stage renal disease (ESRD) patients (1). Although autogenous arteriovenous fistula (AVF) is accepted as the ideal VA and is referred to as a 'lifeline', it is not always easy to construct and AVF creation may cause complications (2). The most frequent complications of AVF are aneurysm, failure to maturation, and thrombosis (3). Among complications of native AVF, symptomatic dialysis access-induced ischemia syndrome (DAIIS), also known as steal syndrome, is rarely seen. On the other hand, it is a serious problem and it may cause some clinical findings like ischemic neuropathy, resting pain, and ulceration or tissue necrosis of fingers that may lead to amputation. It can be seen especially after high volume AVF, and its incidence rate in native AVF varies between 1% and 10% in the literature (4). The objective of this retrospective study is to report our experience with surgical revision of fistulae with DAIIS.

2. Materials and methods
Between January 2005 and July 2013, 1254 patients with ESRD underwent arteriovenous fistula operation, and 86 of them [53 males, mean age: 55 ± 25 (range: 25 to 75) years; 33 females, mean age: 50 ± 20 (range: 30 to 70) years] subsequently developed steal syndrome. These patients were treated with arterial pressure-controlled polytetrafluoroethylene banding or constriction with polypropylene suture technique. Patients were followed in the outpatient clinic at regular intervals.

Results: Symptoms were not relieved during the first 15 days in 4 patients; therefore, reintervention was performed. Thrombosis occurred in one patient after reintervention. No early or late complications were detected in other patients, and fistulae were suitable for hemodialysis. Patency rates at 6 and 12 months were 96% and 92%, respectively, and thrombosis rates were 7% and 9%. There was no hospital mortality in our study, but one patient died from unrelated causes and two other patients quit follow-up after 6 months.

Conclusion: We think that arterial pressure-controlled surgical revision is an effective and safe technique in patients with fistula-related hand ischemia.

Key words: Hemodialysis, arteriovenous fistula, hand ischemia, banding technique

* Correspondence: uhalici2003@yahoo.com
Patients with pain on exercise or during dialysis (stage 2), however, require attention, because of the risk of deterioration to stage 3 (resting pain) or stage 4 (necrosis) in their early phases. These patients were diagnosed by clinical examination and color flow Doppler ultrasound evaluation. Patients with grade 2, 3, and 4 DAIIS were operated on. Some clinical findings of our patients with hand ischemia were pallor and coldness, absence of radial and ulnar artery pulses, intolerable pain under exertion or pain during dialysis, resting pain, cyanosis, and ulcerations of digits. The most common complaint of our patients was pain. The brachial artery and radial artery were cannulated and arterial pressures were monitored and recorded during the operation. We used sterile Doppler ultrasound probe for measurement of AVF flow. Our patients’ fistula mean flow velocity was $900 \pm 100 \text{ mL/min}$. Autogenous AVFs were treated with arterial pressure-controlled PTFE banding and synthetic PTFE grafts were treated with constriction with a polypropylene suturing technique (3 cm distal to AVF anastomoses) (Figures 1 and 2). Our aim was to constrict the AVF until the radiobrachial index was

<table>
<thead>
<tr>
<th>Stage</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1</td>
<td>Retrograde diastolic flow without complaints; steal phenomenon</td>
</tr>
<tr>
<td>Stage 2</td>
<td>Pain on exertion and/or during hemodialysis</td>
</tr>
<tr>
<td>Stage 3</td>
<td>Resting pain</td>
</tr>
<tr>
<td>Stage 4</td>
<td>Ulceration or necrosis or gangrene</td>
</tr>
</tbody>
</table>

Figure 1. Polytetrafluoroethylene banding technique.

Figure 2. Constriction with polypropylene suturing technique.
0.5 in both techniques and intraoperative measurements of flow velocities were approximately 400 mL/min and 600 mL/min in native fistulae and synthetic PTFE grafts, respectively.

Patients were followed in the outpatient clinic at regular intervals. Patients were seen in the outpatient clinic at 1, 3, 6, and 12 months after the surgery. Color flow Doppler ultrasound evaluation was performed and flow velocities were measured for all patients. AVF patency and symptoms of patients were recorded.

3. Results
The most common risk factors of our patients were diabetes mellitus (DM) and peripheral arterial occlusive disease (PAOD). DM was detected in 22 patients (25.5%) and PAOD was detected in 10 patients (11.6%). In our study group, 21 patients (24.4%) had pallor and cold hands (stage 1), but they had no complaints. Sixty patients (69.8%) had intolerable pain under exertion or pain during dialysis treatments and impalpable pulses (stage 2), while 4 (4.7%) patients had resting pain (stage 3) and 1 patient (1.1%) had cyanosis of digits and ulcerations (stage 4).

Symptoms and findings were improved partially or completely by the banding or constriction procedures in all patients. Cyanosis of fingers regressed, finger ulcers were healed partially, and resting and exertion pain subsided. However, complete remission of symptoms were not observed in 4 patients (4.7%) for the first 15 days and in 6 patients (7%) for the first month. Reintervention was performed due to thrombosis. Thrombosis reoccurred in one patient after reintervention. AVF thrombectomy was performed successfully again and the AVF was saved. Patency rates at 6 and 12 months were 96% and 92%, respectively, and thrombosis rates were 7% (6 patients) and 9% (8 patients). Rate of remission of ischemic symptoms at 12 months was 98.72%. Limb salvage rate at 12 months was 100%. There was no hospital mortality in our study, but one patient died from unrelated causes and two patients quit follow-up after 6 months.

4. Discussion
AVF is a surgically created connection between an artery and vein in patients with end-stage renal failure. The native AVF is the optimum option for hemodialysis patients, as it is associated with lower complication rates compared to other forms of hemodialysis accesses (7). AVFs might have hemodynamic complications, which may lead to neurological or ischemic problems. The pathophysiologic mechanisms of DAIIS are complex and poorly understood. Shunting of blood away from high-resistance arm and forearm arteries to a low-resistance area in arteriovenous access, resulting in hypoperfusion distal to the anastomosis, has been generally assumed to be the reason. Furthermore, presence of arterial stenosis beyond the AVF anastomosis may also play a critical role in the etiology (8). Ischemic neuropathy can be seen due to damage to peripheral nerves because of compromised blood supply. Treatment should be started with a detailed history and physical examination to rule out nonischemic causes of hand pain of patients with AVF. Advanced age, diabetes, female sex, PAOD, large conduits such as femoral or popliteal veins, and history of multiple prior procedures increase the risk of steal syndrome in upper extremities (9). In our study, the most common risk factors of our patients were DM and PAOD, whereas DAIIS was found to be more common in males than females.

The incidence rate of DAIIS requiring an intervention was 6% in our study, which was detected between the 1st and 4th weeks after creation of an AVF. The ideal treatment option for DAIIS must reverse the ischemia while preserving the access; however, there was no ideal treatment for this purpose (10). Stolic et al. (11) reported in their study that they monitored patients with mild DAIIS and a radical approach is not required in these patients. They pointed out that the strategic application of a treatment depends on the severity of symptoms and comorbidities of the patients and the skill of the surgical team (11). We followed the grade 1 patients and did not perform any operations for those patients. We operated on patients with grade 2, 3, and 4 DAIIS.

Catheter-based interventions to repair arterial stenoses, ligation of the access, banding, distal revascularization-interval ligation, revision using distal inflow, and proximal arterial inflow procedures, among others, can be performed for the treatment of symptomatic patients with DAIIS (12). Recently, some investigators have applied percutaneous transluminal angioplasty to treat arterial stenosis with the resolution of hand ischemia and healing of digital ulcers (13). Percutaneous interventions such as intravascular coil insertion, percutaneous balloon angioplasty, and intravascular stent insertion can also be performed to ameliorate DAIIS (8).

Closure of an AVF (ligation) is another option that is chosen by some. Although this intervention improves peripheral circulation immediately and symptoms are relieved, the surgeon has to find a new suitable artery and vein to create a new AVF after closure of the old one. Furthermore, the new fistula needs time to mature, so a hemodialysis catheter is inserted into another vein to ensure hemodialysis during this period. Again, there is a risk of developing ischemia in the new AVF. On the other hand, ligation of the access limits the patient’s long-term access options. Therefore, correction of DAIIS must preserve the access and, at the same time, improve peripheral arterial circulation (14).
Based on reports about unsatisfactory improvement of DAIIS and high rates of AVF thrombosis, the banding technique was not recommended in some studies (15,16). Additionally, there are reports that DAIIS healed in 90% to 100% of patients, while only 10% to 40% of the banded accesses remained patent in some studies (16–18). Mickley (14) reported that low fistula flow rate caused by banding may result in inefficient dialysis therapy or even access thrombosis while DAIIS syndrome disappears. On the other hand, Van Hoek et al. (19) reported that ischemic symptoms attenuated and all patients successfully continued their dialysis therapy after fistula banding of hemodialysis access to treat hand ischemia. Hastaoğlu et al. (20) reported in their study that the continuity of dialysis can be highly sustained in patients with steal syndrome due to dialysis, maintaining the current arteriovenous fistulae through appropriate revision techniques. Özbek et al. (21) reported that controlled banding with brachial and radial artery pressure monitoring reduces the risk of fistula thrombosis and reinterventions (21). In that study, patenty and thrombosis rates at 12 months were 90% and 10%, respectively, and the rate of relief of symptoms was 95%. Likewise, in our study, patenty rates at 6 months and 12 months were 96% and 92%, respectively. On the other hand, thrombosis rates at 6 months and 12 months were 7% and 9%, respectively. Moreover, ischemic symptoms disappeared completely in 89% of our patients.

The access banding technique aims to create a narrow vessel segment within the access or reduce flow through the anastomosis. Native fistulae can be banded by nonabsorbable sutures, small caliber interposition grafts, or by narrowing the vein with a tight Dacron or PTFE cuff (14). In prosthetic accesses, interposition of a short tapered graft segment has also been suggested in the literature (16–18,22,23). An accurate physical examination of the AVF is essential for early diagnosis and timely referral of the patient is necessary to prevent complications (1). We used arterial pressure-controlled PTFE banding and constriction with polypropylene suturing techniques in our patients, in parallel with the literature findings. We are of the opinion that synthetic PTFE graft binding method has more favorable results than the polypropylene suturing method. However, the patient’s vascular structure has an important role.

In conclusion, we think that arterial pressure-controlled surgical revision is an effective and safe technique in patients with arteriovenous fistula-related hand ischemia. This technique also has the advantage of saving veins, which, of course, is worthwhile in patients under hemodialysis treatment.

References


